Download - Heart Failure Society of America

16th Annual Scientific Meeting 

Advance Program & Registration Information 

September 9 – 12, 2012 

Washington State Convention Center 

Seattle, WA 

www.hfsa.org

2 

executive council 

Officers 

Barry M. Massie, MD (President) 

Thomas Force, MD (Vice-President) 

Hani N. Sabbah, PhD (Secretary) 

Mandeep R. Mehra, MD (Treasurer) 

Douglas L. Mann, MD (Immediate Past President) 

Members 

Inder S. Anand, MD, PhD 

John C. Burnett, Jr., MD 

John Chin, MD 

Steven R. Houser, PhD 

Sharon A. Hunt, MD 

JoAnn Lindenfeld, MD 

Sara C. Paul, DNP, FNP 

Mariann Piano, RN, PhD 

Heather J. Ross, MD 

Randall C. Starling, MD, MPH 

James E. Udelson, MD 

Michael R. Zile, MD 

Members (ex officio) 

Jay N. Cohn, MD 

Gary S. Francis, MD 

David A. Lathrop, PhD 

Isabella Liang, PhD 

2012 Scientific Program Committee 

Lynne Warner Stevenson, MD 


Barbara J. Riegel, DNSc, FANN, FAHA 

Larry A. Allen, MD, MHS 

Mark E. Anderson, MD, PhD 

Bikyem Bozkurt, MD 

Harleah G. Buck, RN, PhD, CHPN 

Akshay S. Desai, MD 

Daniel E. Forman, MD 

Jalal K. Ghali, MD 

Joshua I. Goldhaber, MD 

J. Thomas Heywood, MD 

Corrine Y. Jurgens, RN, PhD 

Christopher Lee, RN, PhD 

Annarosa Leri, MD 

Wayne C. Levy, MD 

Douglas W. Losordo, MD 

Leslie W. Miller, MD 

Robert Lee Page, II, PharmD, MSPH 

Michael G. Petty, RN, CCNS, ACNS 

Margaret M. Redfield, MD 

Paul B. Rosenberg, MD 

Douglas D. Schocken, MD 

Jagmeet P. Singh, MD, PhD 

Yibin Wang, PhD 

HFSA Corporate Members 

Amgen 

Boston Scientific 

Janssen Scientific Affairs 

Medtronic, Inc. 

Otsuka Pharmaceuticals 

St. Jude Medical 

Thoratec Corporation 

about HFSa 

advance program 

The Heart Failure Society of America (HFSA) represents the first organized effort by 

heart failure experts from the Americas to provide a forum for all those interested in 

heart failure research and patient care. 

The HFSA is dedicated to: 

❚ Promoting research related to all aspects of heart failure and to providing a forum 

for presentation of basic, clinical and population-based research. 

❚ Educating health care professionals through programs, publications and other 

media in the areas of basic science, clinical medicine, patient management, and 

social, ethical and economic issues to enable them to diagnose and treat heart 

failure and concomitant medical conditions more effectively. 

❚ Encouraging primary and secondary preventive measures to reduce the incidence 

of heart failure; serving as a resource for government, private industry and health 

care providers to facilitate the establishment of programs and policies that will 

better serve the patient. 

❚ Enhancing quality and duration of life in those with heart failure. 

❚ Promoting and facilitating the formal training of physicians, scientists and allied 

health care providers in the field of heart failure. 

membership Information 

Membership in the Society is open to all health care professionals with an interest 

in cardiovascular medicine. For information about the HFSA and how to become a 

member, visit the HFSA website: www.hfsa.org. 

For questions, contact: 

Heart Failure Society of America (HFSA) 

Court International, Suite 240 South 

2550 University Avenue West 

St. Paul, MN 55114 

Phone: (651) 642-1633 

Fax: (651) 642-1502 

Email: info@hfsa.org 

Website: www.hfsa.org


Highlights of the 2012 HFSa annual 

Scientific meeting 

❚ Popular reviews of Clinical Fundamentals updated for 2012 

❚ Excellence in Basic Science featuring Eric N. Olson on Strategies to Repair the 

Ailing Heart 

❚ Plenary session focusing on communication — from electronic feedback loops to 

laureate poetry 

❚ Oral Abstract Presentations including new Featured Oral Session plus two noontime 

rapid-fire sessions — basic science, clinical, and nursing 

❚ Joint ICCAC-VAD session from consent through outcomes and lessons learned 

from myVAD.com 

❚ How-to sessions ranging from trendy — Using Apps for Self-Care to timeless — 

Difficult Conversations About Prognosis 

❚ U-Shaped Curves in Heart Failure — What are they? 

❚ A two-part study session on the MOC self-evaluation module in Advanced Heart 

Failure and Transplant Cardiology 

❚ Strategies for National Heart Failure Care and Envisioning Therapy in Heart 

Failure with commentary by Eugene Braunwald offer wide views of what’s ahead 

❚ Focus on the Readmission Challenge, Performance Measures, and Drug-Device 

Approval Processes in the U.S. 

❚ A Day In The Life from translational clocks to medication schedules for the patient 

with heart failure. 

❚ Integrated basic science from The Human Genome Comes Home to How Should 

We Improve Pump Function? 

❚ Controversies exposed: Reducing Sodium: Fact or Fiction?; Adult Stem Cells vs 

iPS Cells or Real Recovery with VADs?; Three Treatments for Atrial Fibrillation; 

and Implantable vs Non-invasive Home Monitoring. 

❚ And, of course, Case Discussions, Hyde Park, Late-Breaking Science, Debates, 

Posters, Satellite Symposia, Product Theaters, Hands-on Device Workshops, and 

more — all in the beautiful city of Seattle! 

open plenary guest Speakers 

Thomas Goetz is author of The Decision Tree: Taking Control of Your Health in the 

New Era of Personalized Medicine. Former FDA commissioner Dr. David Kessler 

calls The Decision Tree “a game changer,” and Dr. Dean Ornish says that Goetz “writes 

more clearly and presciently about the future of health care than anyone on the planet.” 

The executive editor of WIRED Magazine, Goetz writes frequently on the confluence 

of medicine, health and technology. His cover stories at WIRED have covered the early 

detection of cancer, the advent of personal genomics and the controversial diagnosis of 

metabolic syndrome. His work has been selected for both the Best American Science 

Writing and the Best Technology Writing anthologies. Since Goetz joined WIRED in 

2001, the magazine has been nominated for 12 National Magazine Awards and has won 

six times, including the top award for general excellence three times. 

Billy Collins is an American phenomenon. No poet since Robert Frost has managed to 

combine high critical acclaim with such broad popular appeal. His work has appeared in 

a variety of periodicals including The New Yorker, The Paris Review and The American 

Scholar, and he is a Guggenheim fellow and a New York Public Library “Literary 

Lion.” His last three collections of poems have broken sales records for poetry. His 

readings are usually standing room only, and his audience – enhanced tremendously by 

his appearances on National Public Radio – includes people of all backgrounds and age 

groups. The poems themselves best explain this phenomenon. The typical Collins poem 

opens on a clear and hospitable note but soon takes an unexpected turn; poems that 

begin in irony may end in a moment of lyric surprise. No wonder Collins sees his poetry 

as “a form of travel writing” and considers humor “a door into the serious.” It is a door 

that many thousands of readers have opened with amazement and delight. 

Billy Collins has published nine collections of poetry and was United States Poet 

Laureate 2001-2003. 

general Information 

The 16th Annual Scientific Meeting of the Heart Failure Society of America offers a 

diverse program including basic science, translational and clinical sessions. There is 

something for everyone interested in heart failure. Register before July 30 to receive 

a discount. 

Expected Attendees 

It is anticipated that attendees will include: 

❚ Cardiologists, CV surgeons, internists and primary care physicians 

❚ Clinical researchers 

❚ Cardiac rehabilitation professionals 

❚ Cardiac care nurses 

❚ Epidemiologists 

❚ Health care administrators 

❚ Industry 

❚ Pharmacists 

❚ Research scientists 

Visas/Letters of Invitation 

If you have visa requirements it is highly recommended that you begin the process 

soon. Letters of invitation for visa purposes will be provided by the HFSA office 

upon request. Please email your request to info@hfsa.org. It should be understood 

that the letter of invitation is meant to help members obtain a visa and is not a 

commitment on the part of the organizers to provide any financial support. The 

decision to grant a visa belongs solely to the embassy/consulate. Should your 

application be denied, HFSA cannot change the decision of the government agency. 

Special Needs 

The HFSA strives to hold meetings that are accessible to all. Please tell us what you 

require to help make your participation more enjoyable and meaningful. Contact 

Gudrun Echterhoff, Global Meetings & Incentives at gudrun@global-mtgs.com 

((201) 850-7607). 

Liability Statement 

Disclaimer: The Heart Failure Society of America (HFSA) cannot accept, and hereby 

specifically disclaims, any liability for death, injury, any loss, cost or expense suffered 

or incurred by any person if such loss is caused by, arises from or results from the 

act, default or omission of any person other than an employee or agent of HFSA. In 

particular, neither HFSA nor its agents can accept, and hereby specifically disclaims, 

any liability for losses arising from, caused by, or resulting from, the provision or nonprovision 

of services provided by the hotels, companies, or transport operators. Neither 

HFSA nor its agents can accept, and hereby specifically disclaims, liability for losses 

suffered by reason of war including threat of war, riots and civil strife, terrorist activity, 

natural disaster, weather, fire, flood, drought, technical, mechanical or electrical 

breakdown within any premises visited by delegates and/or participants in connection 

with the meeting, industrial disputes, government action, regulations or technical 

problems that affect or may affect the services provided in connection with the meeting. 

HFSA is not able to warrant and does not warrant that a particular person will appear as 

a speaker. As a condition to any participation in or attendance at the Annual Scientific 

Meeting or any function associated or affiliated herewith, each attendee and participant 

accepts the foregoing disclaimer. 

3

4 

Conference Location 

The 16th Annual Scientific Meeting of the Heart Failure 

Society of America will be held at the Washington State 

Convention Center in Seattle, WA. Located in the heart 

of downtown Seattle, the Center features on-site parking, 

business services and a variety of eateries — all within 

easy walking distance of the city’s best shops, sights, 

hotels and restaurants. 

Hotel 

The Sheraton Seattle Hotel & Towers is located within 

walking distance of the Washington State Convention 

Center and blocks from Seattle’s famed Pike Place Market. 

The hotel features a newly remodeled fitness center, 

expanded lobby, stylish guest rooms, indoor swimming 

pool, business center, restaurants and much more. 

Sheraton Seattle Hotel & Towers 

(Headquarter Hotel) 

1400 Sixth Avenue 

Seattle, WA 98101 

(206) 621-9000 

Rates: $249 Single/Double Occupancy, 

$269 Deluxe Room, $289 Club Level, 

$25 Additional Person 

Taxes: 15.60% 

These rates include in-room high-speed Internet access 

for all guests blocked within the HFSA room block. 

Register Online 

Registration for the 16th Annual Scientific Meeting of the 

Heart Failure Society of America is available online at: 

hfsa.org/registration_info.asp. Online registration requires 

a credit card. If you do not wish to register online, you 

may fill out the form on page 26 of this brochure and 

return the form by mail with payment to: HFSA, Court 

International, Suite 240 South, 2550 University Avenue 

West, St. Paul, MN 55114. 

Registration Fee 

The registration fee includes admittance to all meeting events, including scientific 

sessions, opening reception, poster sessions, satellite symposia and commercial exhibits. 

MOC (Maintenance of Certification): Attendees will need to preregister for these 

sessions. Details will be provided at a later date. 

7th Avenue Entrance 

Entrance Entrance Entrance 

FE 

FE 

Office Tower 

ACT 

Theatre 

Pike Street 

Levels 1-4 

and 

to North Lobby 

10 

FE 

ACT 

To/From 

registration and exhibit Hours 

Registration Hours 

Saturday September 8 1:00 PM – 4:00 PM 

Sunday September 9 8:00 AM – 5:00 PM 

Monday September 10 7:00 AM – 5:00 PM 

Tuesday September 11 7:00 AM – 5:00 PM 

Wednesday September 12 7:00 AM – 10:00 AM 

Exhibit Hours 

Sunday September 9 6:00 PM – 8:00 PM 

Monday September 10 9:30 AM – 7:00 PM 

Tuesday September 11 9:30 AM – 7:00 PM 

i 

Retail 

Retail 

Union Street 


Entrance 

Levels 1-4 

and to 

South Lobby 

An application to exhibit and an exhibit prospectus may be obtained by contacting the 

HFSA at info@hfsa.org, (651) 642-1633/fax: (651) 642-1502. You may also download 

a copy at hfsa.org (annual scientific meeting). 

Fountain 

South 

Galleria 

Entrance 

$ 

Business 

Center 

Entrance 

N 

Retail 

FE 

TDD 

FE 

To 

Convention 

Center 

Parking 

Garage 

Entrance

SeaTTLe: a deSTInaTIon 

Attractions 

The 605-foot-high Space Needle, built for the 1962 World’s Fair, is Seattle’s number 

one tourist destination. It provides one of the best views of the city, the Puget Sound 

and the surrounding mountains. A visit to Seattle wouldn’t be complete without a stop 

at Pike Place Market. The famous attraction occupies a 9-acre area along the water 

and features fresh local produce, food, crafts and gifts. Don’t miss the fishmongers 

and catchers at the market who entertain visitors by tossing around fish to each other 

across their stands. 

Arts & Culture 

The Seattle Art Museum features an outstanding permanent collection and an everchanging 

rotation of special exhibits from around the world. The Henry Art Gallery 

is home to exciting new works, while the Frye Art Museum serves up both classic 

and contemporary paintings. The nation’s finest collections of Korean, Chinese and 

Japanese art are housed at the Seattle Asian Art Museum in Volunteer Park and the 

original Air Force One is displayed at the popular Museum of Flight. 

Restaurants 

Seattle’s diverse population and proximity to the Puget Sound contribute to some of 

the best seafood, sushi and Japanese food in the Pacific Northwest. If seafood is not 

your thing, there is an abundance of cuisines from which to choose. From upscale 

steakhouses and Italian restaurants to welcoming coffee shops — including the 

original Starbucks — and specialty bakeries, the city is awash with casual and fine 

dining establishments to satisfy any palette. 

Shopping 

Downtown Seattle features all the brand names you know and love, including 

Nordstrom, Gap, J. Crew and Ann Taylor, while the Fremont shopping district is a 

haven for lovers of retro and vintage shops. The International District, or the ID as 

it’s known, is just southeast of Pioneer Square and highlights the tastes and sights of 

Asia. Pike Place is the place to go for handmade arts, crafts and other local wares. 

And, as its name implies, the university area caters to the University of Washington’s 

collegiate crowd with cheap eats and a mix of chain stores and boutiques. 

5

6 

ce Information 

Learning Objectives 

Following this meeting, participants will be able to: 

❚ Describe the epidemiology of heart failure and implement strategies for the 

prevention of heart failure. 

❚ Describe current knowledge about the scientific basis of heart failure at the levels 

of cardiovascular physiology, neurohormones, tissue factors, and molecular 

biology and genetics. 

❚ Identify the findings of basic science and current clinical trials and discuss their 

implications for current and future heart failure therapy. 

❚ Implement optimal guideline-based therapeutic options for heart failure, including 

pharmacologic agents; non-pharmacologic options, such as diet and exercise; and 

device-based therapies. 

❚ Manage comorbidities, including hypertension, diabetes and depression. 

❚ Demonstrate awareness of psychosocial, economic and ethical issues in the 

treatment of patients with heart failure. 

❚ Implement strategies for effective management of the patient with heart failure, 

incorporating the family, encouraging self-care and employing the medical home 

model. 

❚ Outline strategies for transitioning patients from inpatient to outpatient care and 

for reducing hospital readmissions. 

❚ Engage in performance measurement and other site-based research. 

❚ Communicate effectively with patients, families and other health professionals. 

Individual session objectives are listed after each session in the program book. 

Scientific Program 

The Heart Failure Society of America is accredited by the Accreditation Council for 

Continuing Medical Education to provide continuing medical education for physicians. 

The Heart Failure Society of America designates this live activity for a maximum of 25 

AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate 

with the extent of their participation in the activity. 

This program has been approved by the American Association of Critical Care Nurses 

(AACN) for 24.5 Contact Hours, Synergy CERP Category A, File number 00017881. 

Badges will be scanned automatically as attendees enter a session, including satellite 

symposia. This information will be used to verify attendance for CME and CNE credits 

and will not be sold or shared with 

anyone outside the HFSA. 

Satellite Symposia 


Credit will be provided for physicians and nurses. Two-hour satellites provide 2 hours 

of credit; 1-hour satellites provide 1 hour. 

Poster Sessions 

Poster sessions provide an opportunity for interaction between the poster authors 

and attendees. Posters are listed in the final program booklet and are on display 

Monday, September 10, and Tuesday, September 11, 9:30 AM - 7:00 PM. Authors 

will be at their posters both days from 5:45-6:45 PM. 

Satellite Symposia 

These one- or two-hour symposia, often focusing on recent research and emerging 

therapeutic options, are planned using the same criteria that apply to the scientific 

program. They are reviewed and approved by the HFSA Satellite Symposium Review 

Committee and provide CME and CNE credit. 

Satellite attendees must be registered for the Annual Scientific Meeting. No 

additional registration or fee is required. Satellites are held Sunday afternoon and 

Monday and Tuesday mornings. 

Information about satellite symposia will be posted online at www.hfsa.org as 

programs are finalized. All satellite symposia are included in the final program book.

advance program: confirmed Faculty 

Keith D. Aaronson, MD, MS 

University of Michigan 

Ann Arbor, MI 

William T. Abraham, MD 

The Ohio State University 

Columbus, OH 

Michael A. Acker, MD 

University of Pennsylvania 

Philadelphia, PA 

Philip B. Adamson, MD 

Oklahoma Heart Hospital 

Oklahoma City, OK 

Felipe Aguel, PhD 

Food and Drug Administration/CDRH 

Silver Spring, MD 

David Aguilar, MD 

Baylor College of Medicine 

Houston, TX 

Ali Ahmed, MD, MPH 

University of Alabama at Birmingham 

Birmingham, AL 

Nancy M. Albert, RN, PhD 

Cleveland Clinic Foundation 

Cleveland, OH 

Larry A. Allen, MD, MHS 

University of Colorado 

Aurora, CO 

Inder S. Anand, MD, PhD 

Minneapolis VAMC 

Minneapolis, MN 

Stefan D. Anker, MD, PhD 

Charite, Campus Virchow-Klinikum 

Berlin, Germany 

Ross Arena, PT, PhD 

The University of New Mexico 

Albuquerque, NM 

Gust H. Bardy, MD 

Seattle Institute for Cardiac Research 

Bellevue, WA 

Denise D. Barnard, MD 

University of California, San Diego 

San Diego, CA 

Donald M. Bers, PhD 

University of California, Davis 

Davis, CA 

Lenore J. Blank, RN, MSN, NP-C 

Mahwah, NJ 

Burns C. Blaxall, PhD 

University of Rochester 

West Henrietta, NY 

Ann Bolger, MD 

University of California, San Francisco 

San Francisco, CA 

Jeffrey S. Borer, MD 

SUNY Downstate Medical Center 

Brooklyn, NY 

Robert C. Bourge, MD 

University of Alabama at Birmingham 

Birmingham, AL 

Steven W. Boyce, MD 

Washington Regional Cardiac Surgery, PC 

Washington, DC 

Biykem Bozkurt, MD 


Houston, TX 

Eugene Braunwald, MD 

Brigham and Women’s Hospital 

Boston, MA 

Michael R. Bristow, MD, PhD 


Aurora, CO 

Harleah G. Buck, RN, PhD, CHPN 

The Pennsylvania State University 

University Park, PA 

Daniel Burkhoff, MD, PhD 

Columbia University 

New York, NY 

Javed Butler, MD, MPH 

Emory University 

Atlanta, GA 

Peter Buttrick, MD 


Aurora, CO 

James H. Caldwell, MD 

University of Washington 

Seattle, WA 

Thomas P. Cappola, MD, ScM 



Blase A. Carabello, MD 

VA Medical Center 

Houston, TX 

Peter E. Carson, MD 

Washington VAMC 

Washington, DC 

Donald E. Casey, Jr., 

MD, MPH, MBA 

Atlantic Health System 

Morristown, NJ 

Horng H. Chen, MB, BCh 

Mayo Clinic and Foundation 

Rochester, MN 

Suzanne Chillcott, BSN, RN 

Sharp Memorial Hospital 

San Diego, CA 

John Chin, MD 

Sutter Memorial Hospital 

Sacramento, CA 

Dawn M. Christensen, 

MS, FNP-BC, ACNP-BC 

Penn State University 

Hershey, PA 

Eugene S. Chung, MD 

The Ohio Heart and Vascular Center 

Cincinnati, OH 

John G.F. Cleland, MD 

University of Hull 

Kingston-Upon-Hull, United Kingdom 

Barbara A. Cockrill, MD 


Boston, MA 

Robert J. Cody, MBA, MD 

Merck & Co., Inc. 

Whitehouse Station, NJ 

Jay N. Cohn, MD 

University of Minnesota 


Billy Collins 

Steven Barclay Agency 

Petaluma, CA 

Monica M. Colvin-Adams, MD, MS 



William G. Cotts, MD 

Northwestern University 

Chicago, IL 

Jennifer Cowger, MD, MS 


Ann Arbor, MI 

Sharlene M. Day, MD 


Ann Arbor, MI 

Teresa De Marco, MD 



Prakash C. Deedwania, MD 

VA Central California Health Care System 

Fresno, CA 

Colleen Delaney, RN, PhD, AHN-BC 

University of Connecticut 

Storrs, CT 

Mario C. Deng, MD 

UCLA 

Los Angeles, CA 

David DeNofrio, MD 

Tufts Medical Center 

Boston, MA 

Akshay S. Desai, MD 


Boston, MA 

Anita Deswal, MD, MPH 


Houston, TX 

Marcelo F. Di Carli, MD 


Boston, MA 

Michael G. Dickinson, MD 

West Michigan Heart 

Grand Rapids, MI 

Kenneth Dickstein, MD, PhD 

University of Bergen 

Stavanger, Norway 

Lynn V. Doering, DNSc 

UCLA 


Kathleen A. Dracup, RN, DNSc 



Mark H. Drazner, MD 

University of Texas Southwestern 

Dallas, TX 

Anique Ducharme, MD, MSc 

Montreal Heart Institute 

Montreal, Quebec, Canada 

Mark E. Dunlap, MD 

MetroHealth Medical Center 

Cleveland, OH 

Jean-Bernard Durand, MD 

University of Texas 

Houston, TX 

Victor J. Dzau, MD 

Duke University 

Durham, NC 

Uri Elkayam, MD 

LAC+USC Medical Center 


Jill Howie Esquivel, RN, PhD, NP 



Lorraine S. Evangelista, RN, PhD 

University of California, Irvine 

Irvine, CA 

Michael D. Ezekowitz, MB, ChB, DPhil 

Lankenau Medical Center 

Wynnewood, PA 

James C. Fang, MD 

Case Western University 

Cleveland, OH 

Arthur M. Feldman, MD, PhD 

Temple University 


G. Michael Felker, MD 


Durham, NC 

Mona Fiuzat, PharmD 


Durham, NC 

Gregg C. Fonarow, MD 

UCLA 


Thomas Force, MD 



Paul R. Forfia, MD 



Daniel Forman, MD 


Boston, MA 

Gary S. Francis, MD 



Robert P. Frantz, MD 


Rochester, MN 

Marie Galvao, MSN, ANP-BC, CHFN 

Montefiore Medical Center 

Bronx, NY 

Lior Gepstein, MD, PhD 

Technion-Israel Institute of Technology 

Haifa, Israel 

Robert E. Gerszten, MD 

Massachusetts General Hospital 

Charlestown, MA 

7

8 

Jalal K. Ghali, MD 

DMC Cardiovascular Institute 

Detroit, MI 

Mihai Gheorghiade, MD 


Chicago, IL 

Edward M. Gilbert, MD 

University of Utah Health Science Center 

Salt Lake City, UT 

Michael M. Givertz, MD 


Boston, MA 

Thomas Goetz, MA, MPH 

BrightSight Group, LLC 

Princeton, NJ 

Joshua I. Goldhaber, MD 

Cedars-Sinai Heart Institute 


Steven Goldman, MD 

VA Medical Center 

Tucson, AZ 

Steven R. Goldsmith, MD 

Hennepin County Medical Center 


Sarah J. Goodlin, MD 

Portland VAMC 

Portland, OR 

Stephen S. Gottlieb, MD 

University of Maryland 

Baltimore, MD 

Barry H. Greenberg, MD 


La Jolla, CA 

Robert J. Gropler, MD 

Washington University 

St. Louis, MO 

Michele A. Hamilton, MD 

Cedars-Sinai Medical Center & 

Ronald Reagan UCLA Medical Center 


Paul J. Hauptman, MD 

St. Louis University 

St. Louis, MO 

Adrian F. Hernandez, MD 


Durham, NC 

Ray E. Hershberger, MD 

University of Miami 

Miami, FL 

J. Thomas Heywood, MD 

Scripps Clinic 

La Jolla, CA 

Katherine J. Hoercher, RN 


Cleveland, OH 

Tamara B. Horwich, MD 

UCLA 


Leora I. Horwitz, MD, MHS 

Yale University 

New Haven, CT 




Jonathan G. Howlett, MD 

University of Calgary and Foothills 

Medical Center 

Calgary, AB, Canada 

Sharon A. Hunt, MD 

Stanford University 

Stanford, CA 

Claire Hunter, MD 

Creighton University 

Omaha, NE 

Timothy B. Icenogle, MD 

Northwest Cardiothoracic and Transplant 

Surgeons, PS 

Spokane, WA 

Mariell L. Jessup, MD 



Ranjit John, MBBS 



Jacob Joseph, MB, BS, MD 


Boston, MA 

Corrine Y. Jurgens, RN, PhD 

Stony Brook University 

Stony Brook, NY 

Annemarie Kaan, MCN, RN 

The University of British Columbia 

Vancouver, BC, Canada 

Stuart D. Katz, MD 

New York University Langone 

Medicine Center 

New York, NY 

James N. Kirkpatrick, MD 

Perelman Center for Advanced Medicine 


Michelle M. Kittleson, MD, PhD 

California Heart Center 

Beverly Hills, CA 

Kyle W. Klarich, MD 


Rochester, MN 

Jon A. Kobashigawa, MD 

California Heart Center 

Beverly Hills, CA 

Walter J. Koch, PhD 



Marvin A. Konstam, MD 


Boston, MA 

Robert L. Kormos, MD 

University of Pittsburgh 

Pittsburgh, PA 

Raymond Y-K Kwong, MD 


Boston, MA 

Neal Lakdawala, MD 


Boston, MA 

Rachel J. Lampert, MD 

Yale University 

New Haven, CT 


David E. Lanfear, MD 

Henry Ford Hospital 

Detroit, MI 

Ann S. Laramee, APRN 

Fletcher Allen Healthcare 

South Burlington, VT 

Christopher S. Lee, RN, PhD 

Oregon Health & Science University 

Portland, OR 

Daniel Lee, MD 


Chicago, IL 

Carl V. Leier, MD 

The Ohio State University 

Columbus, OH 

Daniel J. Lenihan, MD 

Vanderbilt University 

Nashville, TN 

Terry A. Lennie, PhD, MS 

University of Kentucky 

Lexington, KY 

Jane A. Leopold, MD 


Boston, MA 

Annarosa Leri, MD 


Boston, MA 

Wayne C. Levy, MD 


Seattle, WA 

E. Douglas Lewandowski, PhD 

University of Illinois 

Chicago, IL 

Eldrin F. Lewis, MD, MPH 


Boston, MA 

Gregory D. Lewis, MD 


Boston, MA 

Joseph R. Libonati, PhD 



Giuseppe Licata, MD 

Università degli Studi di Palermo 

Palermo, Italy 

Kelly Ann Light-McGroary, MD 

University of Iowa 

Iowa City, IA 

JoAnn Lindenfeld, MD 


Aurora, CO 

Peter P. Liu, MD 

University of Toronto 

Toronto, ON, Canada 

Douglas W. Losordo, MD 


Chicago, IL 

W. Robb MacLellan, MD 


Seattle, WA 

Calum A. MacRae, MD, PhD 


Boston, MA 

Alan S. Maisel, MD 


La Jolla, CA 

Douglas L. Mann, MD 


St. Louis, MO 

Eduardo Marbán, MD, PhD 

Cedars-Sinai Medical Center 


Kenneth B. Margulies, MD 



Frederick A. Masoudi, MD, MSPH 


Aurora, CO 

Barry M. Massie, MD 

VA Hospital 


Simon W. Maybaum, MD 

Montefiore Medical Center 

Bronx, NY 

John T. McDevitt, PhD 

Rice University 

Houston, TX 

Edwin C. McGee, Jr., MD 


Chicago, IL 

Elizabeth M. McNally, MD, PhD 

The University of Chicago 

Chicago, IL 

Mandeep R. Mehra, MD 


Boston, MA 

JonDavid Menteer, MD 

University of Southern California 


Theo E. Meyer, MD, PhD 

University of Massachusetts 

Worcester, MA 

Alan B. Miller, MD 

University of Florida 

Jacksonville, FL 

Leslie W. Miller, MD 

University of South Florida 

Tampa, FL 

Gordon W. Moe, MD 

St. Michael’s Hospital 


Jeffery D. Molkentin, PhD 

Cincinnati Children’s Hospital 

Medical Center 

Cincinnati, OH 

Debra K. Moser, RN, DNSc 


Lexington, KY 

Gia Mudd-Martin, PhD, MPH, RN 


Lexington, KY 

Mark A. Munger, PharmD 

University of Utah 


Michael D. Murray, PharmD, MPH 

Regenstrief Institute, Inc. 

Indianapolis, IN


Charles E. Murry, MD, PhD 


Seattle, WA 

Sanjiv M. Narayan, MD, PhD 


La Jolla, CA 

Tien M.H. Ng, PharmD 



Anju Nohria, MD 


Boston, MA 

John B. O’Connell, MD 

Heart Failure Consultants 

Atlanta, GA 

Christopher M. O’Connor, MD 


Durham, NC 

Eric N. Olson, PhD 


Dallas, TX 

Anjali Tiku Owens, MD 



Milton Packer, MD 


Dallas, TX 

Robert Lee Page, II, PharmD, MSPH 

UCHSC School of Pharmacy 

Aurora, CO 

Peter S. Pang, MD 


Chicago, IL 

Soon J. Park, MD 


Rochester, MN 

Ayan R. Patel, MD 


Boston, MA 

J. Herbert Patterson, PharmD 

University of North Carolina 

Chapel Hill, NC 

Sara C. Paul, RN, MSN, DNP 

Western Piedmont Heart Centers 

Hickory, NC 

Dudley J. Pennell, MD, FRCP 

Royal Brompton and Harefield NHS Trust 

London, United Kingdom 

Pamela N. Peterson, MD, MSPH 


Denver, CO 

Michael G. Petty, RN, CCNS, PhD 



George J. Philippides, MD 

Boston University 

Boston, MA 

Mariann R. Piano, RN, PhD 

University of Illinois 

Chicago, IL 

Philippe Pibarot, DVM, PhD 

Institut Universitaire de Cardiologie et 

de Pneumologie de Quebec 

Quebec, QC, Canada 

Ileana L. Piña, MD 

Albert Einstein College of Medicine 

Bronx, NY 

Peipei Ping, PhD 

UCLA 


Bertram Pitt, MD 


Ann Arbor, MI 

Jeanne E. Poole, MD 


Seattle, WA 

Michael A. Portman, MD 

Seattle Children’s 

Seattle, WA 

Susan J. Pressler, RN, PhD 


Ann Arbor, MI 

Margaret M. Redfield, MD 


Rochester, MN 

Shelby D. Reed, PhD, RPh 


Durham, NC 

Michael W. Rich, MD 


St. Louis, MO 

Barbara J. Riegel, RN, DNSc 



Jo Ellen Rodgers, PharmD 

The University of North Carolina 

Chapel Hill, NC 

Joseph G. Rogers, MD 


Durham, NC 

Paul Rosenberg, MD 


Durham, NC 

Denis Roy, MD 


Montreal, QC, Canada 

Stuart D. Russell, MD 

Johns Hopkins University 

Baltimore, MD 

Jason W. Ryan, MD 

University of Connecticut 

Farmington, CT 

Hani N. Sabbah, PhD 

Henry Ford Health System 

Detroit, MI 

Mitchell T. Saltzberg, MD 

Christiana Care Hospital 

Newark, DE 

William H. Sauer, MD 


Aurora, CO 

Mitzi M. Saunders, RN, PhD, ACNS-BC 

University of Detroit Mercy 

Detroit, MI 

Douglas B. Sawyer, MD, PhD 

Vanderbilt University 

Nashville, TN 

Leslie A. Saxon, MD 



Kristen G. Schaefer, MD 

Dana-Farber Cancer Institute 

Boston, MA 

Douglas D. Schocken, MD 


Durham, NC 

Soko Setoguchi-Iwata, MD, MPH 


Durham, NC 

Marc A. Silver, MD 

Christ Hospital and Medical Center 

Oak Lawn, IL 

Jagmeet P. Singh, MD, PhD 


Boston, MA 

Jared L. Skillings, PhD 

Pine Rest Northeast Clinic 

Grand Rapids Charter Township, MI 

Michael J. Sole, MD 

Toronto General Hospital 


Randall C. Starling, MD, MPH 


Cleveland, OH 

Josef Stehlik, MD, MPH 

University of Utah Hospital 


Lynne Warner Stevenson, MD 


Boston, MA 

William G. Stevenson, MD 


Boston, MA 

Garrick C. Stewart, MD 


Boston, MA 

Wendy Gattis Stough, PharmD 

Expert Medical Communications 

& Consulting, LLC 

Cary, NC 

Mark D. Sullivan, MD, PhD 


Seattle, WA 

Nancy K. Sweitzer, MD, PhD 

University of Wisconsin 

Madison, WI 

Mario Talajic, MD 


Montreal, QC, Canada 

W.H. Wilson Tang, MD 


Cleveland, OH 

David O. Taylor, MD 


Cleveland, OH 

John R. Teerlink, MD 

San Francisco VAMC 


Andre Terzic, MD, PhD 


Rochester, MN 

Jeffrey J. Teuteberg, MD 

University of Pittsburgh 

Pittsburgh, PA 

Rong Tian, PhD, MD 


Seattle, WA 

Robin J. Trupp, RN, PhD, APRN-BC 

Comprehensive CV Consulting 

Tampa, FL 

Emily J. Tsai, MD 



Carsten Tschöpe, MD 

Charite - University Medicine Berlin 

Berlin, Germany 

Patricia A. Uber, PharmD 

University of Maryland 

Baltimore, MD 

James E. Udelson, MD 


Boston, MA 

Mary N. Walsh, MD 

St. Vincent Heart Center of Indiana 

Indianapolis, IN 

Thomas J. Wang, MD 


Boston, MA 

Yibin Wang, PhD 

UCLA 


Robert G. Weiss, MD 

Johns Hopkins University 

Baltimore, MD 

Cheryl A. Westlake, RN, PhD 

Asuza Pacific University 

San Clemente, CA 

Bruce L. Wilkoff, MD 


Cleveland, OH 

Suzanne J. Wingate, RN, PhD 

Gaithersburg, MD 

Ronald M. Witteles, MD 


Stanford, CA 

Mary A. Woo, RN, DNSc 

UCLA 


Joseph Wu, MD 


Stanford, CA 

Clyde W. Yancy, MD, MSc 


Chicago, IL 

Michael R. Zile, MD 

Medical University of South Carolina 

Charleston, SC 

Mark J. Zucker, MD, JD 

Newark Beth Israel Medical Center 

Newark, NJ 

9

10 

program at a glance 

Sunday, September 9, 2012 

10:30 AM Clinical Fundamentals: 

Initial Evaluation and 

Standard Therapies 

1:00 PM Satellite Symposium Satellite Symposium Satellite Symposium Satellite Symposium 

3:00 PM Joint Session 

4:00 PM Satellite Symposium Satellite Symposium Satellite Symposium 

ICCAC-VAD 

(3:30-6:00 PM) 

6:00-8:00 PM Opening Reception 16 th Annual Scientific Meeting Poster-Exhibit Area (Exhibit Hall) 

Monday, September 10, 2012 

8:00 AM Welcome/Opening Remarks 

8:10 AM 2012 HFSA Lifetime Achievement Award 

8:25 AM Presidential Address 

8:40 AM Opening Plenary Session: Communication in a New World 

10:00 AM Coffee Break: Exhibit Hall (posters displayed 9:30 AM-7:00 PM) 

10:30 AM Symposium I: 

Late Breaking News 

12:00 PM Lunch Break 

Symposium II: 

Window Into the Heart 

Nursing Investigator Research Award Session Symposium III: 

Stem Cell Controversies 

12:30 PM Rapid Fire Session (12:30-1:45 PM) (5) How-to Sessions (12:30-1:30 PM) 

2:00 PM Symposium IV: 

Management in 

Nursing Homes 

Symposium V: 

Pharmacology and 

Pharmacokinetics 

101: Applying Theory 

to Patient Care 

JNC New Investigator: 

Clinical/Physiology 

Session 

3:30 PM Coffee Break: Exhibit Hall (posters displayed 9:30 AM-7:00 PM) 

4:00 PM Symposium VIII: 

Mineralocorticoid 

Receptor Antagonists 

(MRAs) 

Symposium IX: 

U Shaped Curves in 

Heart Failure 

Symposium X: 

The Human Genome 

Comes Home 

HFSA Study Session 

for MOC: Part I 

Symposium XI: 

The Transition from 

Hospital to Home 

5:30 PM Wine and hors d’oeuvres in Poster/Exhibit Area (presenters at their posters from 5:45-6:45 PM) 

7:00 PM Exhibits Close (Exhibit Hall open 9:30 AM-7:00 PM) 


Symposium VI: 

A Day in the Life 

HFSA Study Session 

for MOC: Part II 

Special Sunday Scientific 

Session: Excellence in Basic 

Science (3:30-6:00 PM) 

Symposium VII: 

Next Generation 

Beta-Blocker Therapy 

for Heart Failure: 

Genes, Targets, and 

Mechanisms 

JNC New Investigator: 

Basic Science 

Session


program at a glance 

Tuesday, September 11, 2012 


Management of Arrhythmia Devices, and Pulmonary Hypertension 

8:30 AM Symposium XII: 

Advanced Therapy: 

Getting It Right 

Symposium XIII: 

Atrial Fibrillation in 

Heart Failure (Joint 

Session HRS) 

Symposium XIV: 

Restricting Sodium: 

Truth or Tradition? 

10:00 AM Coffee Break: Exhibit Hall (posters displayed 9:30 AM-7:00 PM) 

10:30 AM Symposium XVII: 

Case Discussion 

12:00 PM Lunch Break 

Symposium XVIII: 

Cardiac Metabolism 

in Heart Failure 

Symposium XIX: 

How Can We Test 

New Therapies in 

the US? 

Roundtable: 

Strategies for National Heart Failure Care 

Symposium XV: 

Connecting the Dots 

Between the Disease 

and the Symptoms 

Featured Oral 

Abstract Session 

Symposium XX: 

Approach to Myocarditis/Strategy to 

Recover LV with LVAD (HFSA/European 

Joint Session) 

12:30 PM Rapid Fire Session (12:30-1:30 PM) (5) How-to Sessions (12:30-1:30 PM) 

1:45 PM Announcement of Awards 

2:00 PM Hyde Park 

Session 

Symposium XXII: 

Back in the Hospital 

Symposium XXIII: 

Therapies in Development 

3:30 PM Coffee Break: Exhibit Hall (Posters Displayed 9:30 AM-7:00 PM) 

4:00 PM Symposium XXV: 

Debate Session 

Symposium XXVI: 

Revised AHA/ACC Performance Measures 

and Evidence that Supports Changes 

Symposium XXVII: 

Remodeling in 

Reverse 

5:30 PM Wine and hors d’oeuvres in Poster/Exhibit Area (presenters at their posters from 5:45-6:45 PM) 

7:00 PM Exhibits Close 

Wednesday, September 12, 2012 


Options for Advanced Heart Failure and Clinical Pearls 

8:15 AM HFSA Business Meeting 

8:30 AM Symposium XXIX: 

Cardiotoxicity 

10:00 AM Coffee Break: Meeting Foyer Areas 

10:30 AM Symposium XXXII: 

Envisioning Therapy in Heart Failure 

Symposium XXX: 

Advances in Diagnosis and Targeted Management 

Strategies of Specific Cardiomyopathies 

Symposium XXXIII: 

Re-defining Success 

12:00 PM Scientific Meeting Adjourned. 17th Annual Scientific Meeting: September 22-25, 2013, Orlando, Florida 

Symposium XXIV: 

From Left to Right 

Symposium XVI: 

How Should We 

Improve Pump 

Function? 

Symposium XXI: 

The Patient with Heart 

Failure and Severe 

Valvular Heart Disease 

Symposium XXVIII: 

Drugs Don’t Work in Patients Who Don’t 

Take Them: Why Aren’t Patients Adherent? 

Symposium XXXI: 

Decreasing Readmission From Home 

Symposium XXXIV: 

Common Sense and Personalized Medicine 

11

12 

SUNDAY 

Sunday, September 9 

10:30 AM-1:00 PM 

Clinical Fundamentals: 

Initial Evaluation and Standard Therapies 

Moderators: Larry A. Allen, Denver, CO 

Akshay S. Desai, Boston, MA 

10:30 Introduction: The “Typical” Patient 


10:35 History and Clinical Assessment 

Mark H. Drazner, Dallas, TX 

10:45 Family History and Evolving Role of Genetic Testing 

Neal Lakdawala, Boston, MA 

10:55 Imaging and Invasive Assessment of New-Heart Failure 

James E. Udelson, Boston, MA 

11:05 Questions 

11:15 Initial Medical Therapy: Selection, Initiation, and Titration 

of ACE-Inhibitors, Angiotensin Receptor Antagonists and 

Beta-Blockers 

Michelle M. Kittleson, Beverly Hills, CA 

11:30 The ‘Third Drug’: Aldosterone Antagonist, Isordil/ 

Hydralazine, or ARB? 

William G. Cotts, Chicago, IL 

11:40 Other Medical Therapy: Diuretics, Digoxin, Supplements 

Denise D. Barnard, San Diego, CA 

11:50 Questions and Answers 

Faculty 

12:00 Risk Assessment: Assessment of Functional Capacity and Role 

for Cardiac Biomarkers 

TBN 

12:10 HF-PEF: Workup, Pathophysiology and Management 

Prakash C. Deedwania, Fresno, CA 

12:25 Acute Decompensated Heart Failure: Practical Considerations 

and Approach to Management 

Steven R. Goldsmith, Minneapolis, MN 


Faculty 

Learning Objective: Describe methods for evaluating and managing chronic and 

acute HF, including standard drug therapy. 

SPECIAL SUNDAY SCIENTIFIC SESSION 


3:30-6:00 PM 


Excellence in Basic Science: Rebuilding the Failing Heart 

Moderators: Steven R. Houser, Philadelphia, PA 

Jeffrey D. Molkentin, Cincinnati, OH 

3:30* Strategies to Repair the Failing Heart 

6th Distinguished Lecture in Basic Science 

Eric N. Olson, Dallas, TX 

(Award to be presented immediately following lecture) 

4:30* Cardiac-Derived Stem Cells to Rebuild the Failing Heart 

Eduardo Marban, Los Angeles, CA 

5:00* Embryonic Stem Cells to Rebuild the Failing Heart 

Charles E. Murry, Seattle, WA 

5:30* Induced Pluripotent Stem Cells for Cardiac Repair 

Andre Terzic, Rochester, MN 

*includes 5 minute audience discussion 

Learning Objective: Describe emerging strategies using stem cells or fibroblasts to 

repair the failing heart.



3:30-6:00 PM 

Joint Session with ICCAC-VAD 

Moderators: Michael G. Petty, Minneapolis, MN 

Timothy B. Icenogle, Spokane, WA 

Obtaining Consent: What Do You Tell Patients and Families 

Considering VAD Therapy? 

3:30 Setting Expectations: Education or Sales? 

Jeffrey J. Teuteberg, Pittsburgh, PA 

3:40 What if They Say No? Palliative Care Options 

Kristen G. Schaefer, Boston, MA 

3:50 Caregiver Commitment: What Does Support Entail? 

AnneMarie Kaan, Vancouver, BC, Canada 

4:00 Discussion 

How High is the Bar for a “Good” Destination? 

4:10 What Predicted Survival is a “Good” Destination? 

Michael M. Givertz, Boston, MA 

4:20 What Level of Adverse Events is Acceptable? 

Robert L. Kormos, Pittsburgh, PA 

4:30 What Quality of Life Makes a “Good” Destination? 

Suzanne Chillcott, San Diego, CA 


Going Home: Support Outside the Hospital 

4:50 The VAD Community Online: MyAD.com 

Steven W. Boyce, Washington, DC 

5:00 What is the Social Support Necessary For VAD Success? 

Michael G. Petty, Minneapolis, MN 


Programmatic Issues 

5:20 Adjusting Antiocoagulation: Striking a Balance to Prevent 

Embolic Stroke and GI Bleeds 

Ranjit John, Minneapolis, MN 

5:30 What is a Sustainable Ratio of VAD Coordinators to Patients: 

In New and Established Programs 

Dawn M. Christensen, Hershey, PA 


Learning Objective: Identify factors important to the success of VAD therapy and 

how to manage them. 

MONDAY 

OPENING PLENARY SESSION 

Monday, September 10 

8:00-10:00 AM 

8:00 Opening and Welcome Remarks 

Steven R. Houser, Philadelphia, PA 

Lynne Warner Stevenson, Boston, MA 

Barbara J. Riegel, Philadelphia, PA 

8:10 2012 HFSA Lifetime Achievement Award 

Presented by Jay N. Cohn 

8:25 Presidential Address 

Barry M. Massie, San Francisco, CA 

Communication in a New World 

Moderators: Lynne Warner Stevenson, Boston, MA 

Thomas Force, Philadelphia, PA 

8:40 Feedback Loops Wired to Change Biology 

Thomas Goetz, Princeton, NJ 

9:20 Reaching Out for the Words 

Billy Collins, Winter Park, FL 

Learning Objective: Describe ways in which communication at the personal, 

biological, and technological levels affect healthcare. 


10:30 AM-12:00 PM 

Late Breaking News 

Moderators: Jay N. Cohn, Minneapolis, MN 

Barry H. Greenberg, La Jolla, CA 

10:30* TBD 

Commentary: TBN 

10:52* TBD 


11:14* TBD 


11:38* TBD 


*22 minutes allotted: 15 minute presentation, 8 minute commentary 

Learning Objective: Describe the results of recent trials and discuss their 

implications for the care of patients with heart failure. 


10:30 AM-12:00 PM 

Nursing Investigator Research Award 

Moderators: Kathleen A. Dracup, San Francisco, CA 

Susan J. Pressler, Ann Arbor, MI 

5 presentations, TBD 

*10 minute presentation, 8 minute audience discussion 

Learning Objective: Discuss results of recent nursing research and its implications 

for the care of patients with HF. 

13

14 


10:30 AM-12:00 PM 

Window Into the Heart 

Moderators: Marvin A. Konstam, Boston, MA 

Invited 

10:30 A Perfect Cycle 

Ann Bolger, San Francisco, CA 

10:40 Metabolism Through NMR 

Rong Tian, Seattle, WA 

10:55 Shifting Substrates-PET 

James H. Caldwell, Seattle, WA 

11:05 Cardiac Magnetic Resonance Imaging Determines 

Etiology and Viability 

Daniel Lee, Chicago, IL 

11:15 MIBG Imaging to Track Therapies and Prognosis 

James H. Caldwell, Seattle, WA 

11:30 The Picture of Myocardial Inflammation 

Peter P. Liu, Toronto, ON, Canada 


Faculty 

Learning Objective: Identify imaging modalities and their appropriate use in the 

evaluation and management of patients with heart failure. 


10:30 AM-12:00 PM 

Stem Cell Controversies 

Moderators: TBN 

Douglas W. Losordo, Chicago, IL 

CONTROVERSY 


10:30 Why Do We Need iPS Cells if We Have Adult Cardiac 

Stem Cells? 

Invited 

10:40 Why Do We Need Adult Cardiac Stem Cells if We Have 

iPS Cells? 

Charles E. Murry, Seattle, WA 


11:00* Human iPS Cell-Based Therapy: Considerations Before 

Clinical Applications 

Joseph Wu, Chapel Hill, NC 

11:18* Alternative Use of Human iPS Cells: Drug Screening and 

Disease Modeling 

Lior Gepstein, Haifa, Israel 

11:36* Can We Reprogram Cardiac Fibroblasts Into New 

Cardiac Myocytes 

Victor J. Dzau, Durham, NC 

*15 minute presentation, 2-3 minute audience discussion 

Learning Objective: Describe the role and importance of iPS cells and adult stem 

cells in heart failure research and drug testing. 


12:30-1:45 PM 

Rapid Fire Session 

Moderators: Gary S. Francis, Minneapolis, MN 

Peter P. Liu, Toronto, ON, Canada 

15 abstracts “rapid fire,” 3 minutes to present, 

2 minute discussion 

Learning Objective: Discuss findings from recent clinical research in heart failure.



12:30-1:30 PM 

How-to Sessions 

1. How to Identify Treatable Causes of Heart Failure 

Michael M. Givertz, Boston, MA 

David E. Lanfear, Detroit, MI 

Learning Objective: List treatable causes of heart failure and describe clinical 

techniques and procedures to identify them. 

2. How to Bridge Patients to Transplantation with VADs 

Michael A. Acker, Philadelphia, PA 

Josef Stehlik, Salt Lake City, UT 

Learning Objective: Identify clinical issues in the management of patients with 

VADs awaiting transplant and how they can best be managed. 

3. How to Maximize Adherence to Heart Failure Performance Measures 

in the Inpatient and Outpatient Settings 

Marc A. Silver, Oak Lawn, IL 

Mary N. Walsh, Indianapolis, IN 

Learning Objective: Identify heart failure performance measures and describe 

strategies for maximizing adherence in the inpatient and outpatient settings. 

4. Using Tools for Economic Analysis of Management Interventions 

Shelby D. Reed, Durham, NC 

Sara C. Paul, Hickory, NC 

Learning Objective: Use tools to analyze the cost and cost-effectiveness of 

management interventions in heart failure. 

5. Difficult Conversations About Prognosis 

Kristen G. Schaefer, Boston, MA 

Harleah G. Buck, University Park, PA 

Learning Objective: Describe strategies for productive discussions with heart 

failure patients facing a difficult prognosis. 


2:00-3:30 PM 

Management in Nursing Homes 

Moderators: James N. Kirkpatrick, Philadelphia, PA 

Corrine Y. Jurgens, Stony Brook, NY 

2:00* Where Does Disease Management Take Place? 

John B. O’Connell, Atlanta, GA 

2:18* Device Management 

Rachel J. Lampert, New Haven, CT 

2:36* When to Hold, When to Fold 

Ali Ahmed, Birmingham, AL 

2:54* Exercise Guidelines for Heart Failure in Nursing Homes 

Ross Arena, Albuquerque, NM 

3:12* Promoting Self-Care in Patients Discharged Home From 

a Skilled Nursing Facility 

Colleen Delaney, Storrs, CT 


Learning Objective: Describe strategies for the effective evaluation and management 

of patients with heart failure in nursing homes. 


2:00-3:30 PM 

Pharmacology and Pharmokinetics 101: 

Applying Theory to Patient Care 

Moderators: Robert Lee Page, II, Aurora, CO 

Mona Fiuzat, Durham, NC 

2:00* Testing New HF Drugs in Animal Models 

Hani N. Sabbah, Detroit, MI 

2:15* Pharmacokinetics: Heart Failure Impacts on Drug Metabolism 

Robert Lee Page, II, Aurora, CO 

2:30* Drug-Drug Interactions: Pumps, Proteins, and P-450s 

Jo Ellen Rodgers, Chapel Hill, NC 

2:45* Pharmacodynamics: Drug-induced QT Prolongation: 

Is It a Concern? 

Tien M.H. Ng, Rochester, NY 

3:00* Adapting Drug Regimens for the Elderly 

Michael W. Rich, St. Louis, MO 

3:15* Supplements or Prescriptions? PUFAs and Others 


*12 minute presentations, 3 minute discussion 

Learning Objective: Describe the pharmacology of heart failure drugs and its 

implications for patient management. 


2:00-3:30 PM 

HFSA Study Session for MOC: 

Advanced Heart Failure and Transplant Cardiology Part I 

(10 Knowledge Points: Must attend both sessions to earn points) 

Moderators: Ileana L. Piña, Bronx, NY 

Invited 

Learning Objective: Discuss key questions in the epidemiology, pathophysiology, 

and treatment of patients with advanced heart failure. 


2:00-3:30 PM 

Jay N. Cohn New Investigator Award: 

Clinical/Integrative Physiology 

Moderators: Jay N. Cohn, Minneapolis, MN 




Learning Objective: Discuss results of recent research and their implications for the 

treatment of heart failure. 

15

16 


2:00-3:30 PM 

A Day in the Life 

Moderators: Eldrin F. Lewis, Boston, MA 

Mary A. Woo, Los Angeles, CA 

2:00 Night and Day: Hemodynamic Rhythms During 

Ambulatory Monitoring 

Philip B. Adamson, Oklahoma City, OK 

2:10 FEATURED LECTURE 

Diurnal Rhythms at the Translational (or Molecular) Level 

Michael J. Sole, Toronto, ON, Canada 

2:30 Medication Schedules to Optimize Adherence and Benefit 

Michael D. Murray, Indianapolis, IN 


2:45 Optimal Frequency and Intensity of Exercise 

Daniel Forman, Boston, MA 

3:00 Family Dynamics 

Susan J. Pressler, Ann Arbor, MI 

3:15 Circadian Rhythms and Sleep-Disordered Breathing 

James C. Fang, Cleveland, OH 


Learning Objective: Use circadian rhythms and other time-based strategies to 

maximize management of the patient with heart failure. 


2:00-3:30 PM 

Next Generation Beta-Blocker Therapy for Heart Failure: 

Genes, Targets, and Mechanisms 

Moderators: Walter J. Koch, Philadelphia, PA 

J. Herbert Patterson, Chapel Hill, NC 

2:00* Challenges in Beta-Blocker Utilization: Counting the Eligible 

Adrian F. Hernandez, Durham, NC 

2:18* Biased Downstream Signaling 

Burns C. Blaxall, Rochester, NY 

2:36* Next Generation Beta-Blockers for Heart Failure: Isoform 

Specific Targeting 

Michael R. Bristow, Denver, CO 

2:54* Genetic Diversity in Beta-Blocker Therapy 

TBN 

3:12* Beta Blockers: A Class Effect? 

Steven S. Gottlieb, Baltimore, MD 


Learning Objective: Describe emerging ways in which the effectiveness of betablocker 

therapy for heart failure might be increased. 


4:00-5:30 PM 


Mineralocorticoid Receptor Antagonists (MRAs) 

Moderators: Peter E. Carson, Washington, DC 

Randall C. Starling, Cleveland, OH 

4:00 Get with the Guidelines: Does Adherence Assure 

Quality Outcomes? 

Gregg C. Fonarow, Los Angeles, CA 

4:15 MRAs: What is the Evidence to Support Their Use 

Bertram Pitt, Ann Arbor, MI 

4:30 MRAs: What are the Gaps in Adoption? 


4:45 HFSA 2012 Recommendations on the Use of MRA 

Javed Butler, Atlanta, GA 

5:00 Panel Discussion and Case Studies 

Panelists: 


Peter E. Carson, Washington, DC 



Randall C. Starling, Cleveland, OH 

Wendy Gattis Stough, Cary, NC 


Cheryl A. Westlake, San Clemente, CA 

Case #1: A 70 yo African American male with EF 30%, NYHA 

Class III. What is the best to add next? 

Presenter: Nancy K. Sweitzer, Madison, WI 

Case #2: A 35 yo diabetic male post-MI with EF 36% impaired 

renal function. What is the best to add next and how to monitor? 

Presenter: Monica Colvin-Adams, Minneapolis, MN 

Learning Objective: Identify updates and clinical applications of guidelines for the 

treatment of patients with heart failure.



4:00-5:30 PM 

U Shaped Curves in Heart Failure 

Moderators: John G.F. Cleland, Kingston-Upon-Hull, UK 

TBN 

4:00* HbA1C and Heart Failure: Targets for Diabetes in 


David Aguilar, Houston, TX 

4:15* BMI and Heart Failure: To Gain Weight or Lose it? 

Stefan D. Anker, Berlin, Germany 

4:30* Blood Pressure in Heart Failure: Sign of Pump or 

Sign of Load? 

Biykem Bozkurt, Houston, TX 

4:45* Contractility: It Has To Be Just Right 

Steven R. Houser, Philadelphia, PA 

5:00* ICD Benefit and Disease Severity in Heart Failure 

Leslie A. Saxon, Los Angeles, CA 

5:15* Iron and Erythropoietin in Heart Failure: What is Too Much? 

Inder S. Anand , Minneapolis, MN 

*12 minutes with 3 minute discussion after each presentation 

Learning Objective: Describe a common pattern in diverse management issues and 

how it provides guidance for optimum patient care. 


4:00-5:30 PM 

The Human Genome Comes Home 


Thomas P. Cappola, Philadelphia, PA 

4:00* Common Heritable Mutations in CM 

Ray E. Hershberger, Miami, FL 

4:18* GWAs (Genome-Wide Association Studies) for Dummies 

Thomas J. Wang, Boston, MA 

4:36* Genes Causing Both CM and Arrhythmias 

Calum A. MacRae, Boston, MA 

4:54* Correlating Genotype with Phenotype in Cardiomyopathies 

Sharlene M. Day, Ann Arbor, MI 

5:12* Whole Genome Strategies for Cardiomyopathy 

Elizabeth M. McNally, Chicago, IL 


Learning Objective: Discuss current research in the role of genetics in the 

development of cardiomyopathy and its implications for clinical practice. 


4:00-5:30 PM 

The Transition from Hospital to Home 

Moderators: Claire Hunter, Omaha, NE 

Alan B. Miller, Jacksonville, FL 

4:00 Reducing Readmissions: What Can We All Agree On? 

Leora Horwitz, New Haven, CT 

4:10 Does Very Early Follow-up Make a Difference? 

Robin J. Trupp, Tampa, FL 

4:20 Paving the Road Through Rehabilitation 

Michael G. Dickinson, Grand Rapids, MI 

4:30 Questions on the Transition 

4:50 Assessment and Impact of Frailty 

JoAnn Lindenfeld, Denver, CO 

5:00 Management in Montreal 

Anique Ducharme, Montreal, QC, Canada 

5:10 Where is the Medical Home for Medicare Patients With Heart 

Failure and Co-Morbidities? 

Invited 


Learning Objective: Identify factors affecting the transition from hospital to home 

for patients with heart failure and describe ways to manage them. 


4:00-5:30 PM 

HFSA Study Session for MOC: 

Advanced Heart Failure and Transplant Cardiology Part II 

(10 Knowledge Points: Must attend both sessions to earn points) 

Moderators: Ileana L. Piña, Bronx, NY 

Invited 

Learning Objective: Discuss key questions in the epidemiology, pathophysiology, 

and treatment of patients with advanced heart failure. 


4:00-5:30 PM 

Jay N. Cohn New Investigator Award: Basic Science 

Moderators: Walter J. Koch, Philadelphia, PA 

TBN 



Learning Objective: Discuss the results and implications of basic science research in 

heart failure. 

17

18 

TUESDAY 

Tuesday, September 11 

7:00-8:15 AM 

Strategies for National Heart Failure Care 

Moderators: Clyde W. Yancy, Chicago, IL 

7:00 The View from Washington 

Marvin A. Konstam, Boston, MA 


7:15 How Many Patients, How Many Staff? 

Mariell L. Jessup, Philadelphia, PA 

7:23 Nurses, Nurse Practitioners, or Physician Assistants 

Suzanne J. Wingate, Gaithersburg, MD 

7:31 What Costs for Transplant and VADS are Sustainable? 

Joseph G. Rogers, Durham, NC 

7:39 The Michigan Model 

Keith D. Aaronson, Ann Arbor, MI 

7:47 The VA System as a Database Model 


7:55 Panel Discussion 

Learning Objective: Identify factors affecting the transition from hospital to home 

for patients with heart failure and describe ways to manage them. 


7:00-8:15 AM 

Clinical Fundamentals: Management of Arrhythmia 

Devices, and Pulmonary Hypertension 

Moderators: Daniel J. Lenihan, Nashville, TN 

Ayan R. Patel, Boston, MA 

7:00 CRT – Wider Indications, Wider QRS 

Jagmeet P. Singh, Boston, MA 

7:10 ICD-Common and Uncommon Indications and Complications 

Sanjiv Narayan, La Jolla, CA 

7:20 ICD Shocks: Evaluating and Secondary Prevention 

William G. Stevenson, Boston, MA 

7:30 Device Questions 

7:40 Evaluation of Pulmonary Hypertension and Right 

Ventricular Function 

Myung H. Park, Baltimore, MD 

7:50 Specific Causes of Pulmonary Hypertension 

Teresa De Marco, San Francisco, CA 

8:00 Newer Management of Primary and Secondary 

Pulmonary Hypertension 

Robert P. Frantz, Rochester, MN 


Learning Objective: Describe strategies for care of the patient with advanced heart 

failure, including mechanical circulatory support and transplantation. 


8:30-10:00 AM 

Advanced Therapy: Getting It Right 


Moderators: Sharon A. Hunt, Stanford, CA 

Leslie W. Miller, Tampa, FL 

8:30 Referral to Advanced Heart Failure Programs 

Mark J. Zucker, Newark, NJ 

8:40 Significance of ICD Shocks for Prognosis 

Jeanne E. Poole, Seattle, WA 

8:50 Listing for Transplant Depends on Length of List 

Mario C. Deng, Los Angeles, CA 

9:00 Serial Monitoring of the Right Ventricle During HF Progression 

Paul R. Forfia, Philadelphia, PA 

9:10 Not Too Sick or Too Well for a VAD 



9:30 Preventing Rejection and Vasculopathy Without Infection 

or Cancer 

David O. Taylor, Cleveland, OH 


9:45 Too Soon or Too Late for the Hospice Discussion 

Kelly Ann Light-McGroary, Iowa City, IA 


Learning Objective: Describe approaches to key management decisions in care of 

the patient with advanced heart failure. 


8:30-10:00 AM 

Atrial Fibrillation in Heart Failure 

Joint Session with HRS 

Moderators: William G. Stevenson, Boston, MA 

Jagmeet P. Singh, Boston, MA 

8:30 Prevalence of Atrial Fibrillation in HF All EF 

Denis Roy, Montreal, QC, Canada 

8:45 Anticoagulation in AF: Dosing New and Old 

Michael D. Ezekowitz, Wynnewood, PA 

9:00 Anxiety Sensitivity and Benefit of AF Rhythm Control 

Mario Talajic, Montreal, QC, Canada 


Three Approaches to Atrial Fibrillation 

9:20 Anti-arrhythmic Drugs and Rate Control 

William G. Stevenson, Boston, MA 

9:30 Ablation of the Atrial Fibrillation 

Sanjiv Narayan, La Jolla, CA 

9:40 AV Node Ablation and CRT 

Bruce L. Wilkoff, Cleveland, OH 


Learning Objective: Recognize clinical issues in the care of patients with atrial 

fibrillation and choose the best management options.



8:30-10:00 AM 

Restricting Sodium: Truth or Tradition? 

Moderators: Biykem Bozkurt, Houston, TX 


8:30 Hyponatremia: Marker or Target? 

James E. Udelson, Boston, MA 

Point/Counter Point 

8:40 Sodium Restriction is Beneficial in Patients with Heart Failure 

Stuart D. Katz, New York, NY 

8:50 Sodium Restriction Can Be Harmful in Patients with 


Giuseppe Licata, Palermo, Italy 


9:05 Can We Develop a Drug to Diminish Thirst 

Robert J. Cody, Whitehouse Station, NJ 


9:25 Fluid Restriction in Patients with Heart Failure: 

When is it Needed? 

J. Thomas Heywood, La Jolla, CA 

9:45 One Size Does Not Fit All 

Terry A. Lennie, Lexington, KY 


Learning Objective: Discuss what is known about the role of sodium restriction in 

heart failure and selected strategies for successful implementation. 


8:30-10:00 AM 

Connecting the Dots Between the Disease and 

the Symptoms 

Moderators: Katherine J. Hoercher, Cleveland, OH 

Mark D. Sullivan, Seattle, WA 

8:30 How Does EF Affect the Symptoms of Heart Failure? 

Michael R. Zile, Charleston, SC 

8:40 Who Knows Best? Using The Patient Symptom Report 

Corrine Y. Jurgens, Stony Brook, NY 

8:50 I am Short of Breath – Clinical and Hemodynamic Diagnosis 

Stuart D. Russell, Baltimore, MD 

9:05 BNP Fragments: Potent or Passengers? 

Horng H. Chen, Rochester, MN 

9:15 Discussion of Diagnosis 

9:20 Tracking Changes at Home 

Eugene S. Chung, Cincinnati, OH 

9:35 PDE-5 Inhibitors – Treating the Disease or the Symptoms? 

Gregory D. Lewis, Boston, MA 

9:45 Symptom Burden and Palliation 

James N. Kirkpatrick, Philadelphia, PA 


Learning Objective: Describe the physiological basis of heart failure symptoms and 

the role of selected symptoms in patient care. 


8:30-10:00 AM 

How Should We Improve Pump Function? 

Moderators: Burns C. Blaxall, Rochester, NY 

Douglas L. Mann, St. Louis, MO 

8:30* Contractility Modulation or Smaller Assist Devices for 

Earlier Use? 

Daniel Burkhoff, New York, NY 

8:45* Autonomic Modulation – For The Periphery or The Heart? 

Mark E. Dunlap, Cleveland, OH 

9:00* New Targets for Inotropic Therapy 

Walter J. Koch, Philadelphia, PA 

9:15* How Can Negative Inotropic Agents Improve Cardiac Function 

Joshua I. Goldhaber, Los Angeles, CA 

9:30* IV Inotropic Therapy at Home 

Lenore J. Blank, Mahwah, New Jersey 

9:45* Can CaMKII Inhibitors Affect the Function of the 

Failing Heart? 

Donald M. Bers, Davis, CA 

*12 minute presentation, 3 minute discussion 

Learning Objective: Describe ways in which emerging devices and inotropic therapy 

can impact cardiac function in heart failure. 


8:30-10:00 AM 

Featured Oral Abstract Session 

Moderators: Lynne V. Doering, Los Angeles, CA 


6 abstracts, TBD 

*15 minutes each (10 minute presentation, 5 minute discussion) 

Learning Objective: Discuss findings from recent research in heart failure and their 

implications for heart failure research and treatment. 


10:30 AM-12:00 PM 

Case Discussion 

Case Presenters: James C. Fang, Cleveland, OH 

Gary S. Francis, Minneapolis, MN 

Panelists: Michele A. Hamilton, Los Angeles, CA 

Soon J. Park, Rochester, MN 

Patricia A. Uber, Baltimore, MD 

Sara C. Paul, Hickory, NC 

Mario Talajic, Montreal, QC, Canada 

Learning Objective: Using practice guidelines, research findings and clinical 

experience, make decisions about the management of difficult cases in heart failure. 

19

20 


10:30 AM-12:00 PM 

Cardiac Metabolism in Heart Failure 

Moderators: Michael A. Portman, Seattle, WA 

TBN 

10:30* Metabolic Remodeling in Human Heart Failure 

Robert J. Gropler, St. Louis, MO 

10:48* Novel Metabolic Therapies on the Horizon? 

E. Douglas Lewandowski, Chicago, IL 

11:06* Mitochondrial Metabolism in HF 

W. Robb MacLellan, Seattle, WA 

11:34* Metabolic Therapeutics in the Failing Heart 

Robert G. Weiss, Seattle, WA 

11:52* Perturbations of Mitochondrial Proteome in the 

Failing Myocardium 

Peipei Ping, Los Angeles, CA 


Learning Objective: Describe the role of cardiac metabolism in remodeling and 

cardio-protection and the role of emerging metabolic therapies. 


10:30 AM-12:00 PM 

How Can We Test New Therapies in the US? 

Moderators: Mihai Gheorghiade, Chicago, IL 

TBN 

10:30 Introduction 

Mihai Gheorghiade, Chicago, IL 

10:35 Industry Point of View 

TBN 

TBN 

11:05 FDA Point of View 

Felipe Aguel, Silver Spring, MD 

11:30 European Drugs/Devices Ahead of the US 

Kenneth Dickstein, Stavanger, Norway 


Learning Objective: Describe the role of national policies on the development of 

new heart failure therapies in the US and Europe and discuss ways to enhance 

research and development. 


10:30 AM-12:00 PM 


Approach to Myocarditis/Strategy to Recover LV with LVAD 

HFSA/European Joint Session 

Moderators: Invited 


Role of Anti-myocardia Abs: Cause or Result of Injury? 

10:30 Anti-myocardial Antibodies and Persistent Virus 

in Cardiomyopathy 

Carsten Tschöpe, Berlin, Germany 

10:45 The Role of Biopsy and Testing for Antibodies 

Invited 


Recovery is Real with VADs 

11:15 European Experience with VAD Recovery – Different Patients 

or Different Patience? 

Invited 

11:30 US Experience with Recovery 

Simon W. Maybaum, Bronx, NY 


Learning Objective: TBD 


10:30 AM-12:00 PM 

The Patient with Heart Failure and Severe Valvular 

Heart Disease 

Moderators: Blase A. Carabello, Houston, TX 

Invited 

10:30 The Low Gradient Low EF AS Patient 

Philippe Pibarot, Quebec, QC, Canada 

10:45 Dogs and People with Functional MR 

Blase A. Carabello, Houston, TX 

11:00 The Patient with Advanced AR 

Jeffrey S. Borer, Brooklyn, NY 

11:15 The Patient with Valvular Heart Disease and Lung Disease: 

When Will Fixing the Valve Fix the Dyspnea? 

Barbara A. Cockrill, Boston, MA 

11:30 Can I Ignore TR in My Patient with Left-Sided Valvular 

Heart Disease? 

Edwin C. McGee, Jr., Chicago, IL 


Learning Objective: Describe surgical approaches to the heart failure patient with 

valvular disease.



12:30-1:30 PM 

Rapid Fire Session 

Moderators: Arthur M. Feldman, Philadelphia, PA 

Carl V. Leier, Columbus, OH 

12 abstracts “rapid fire,” TBD 

*3 minutes to present, 2 minute discussion 

Learning Objective: Discuss findings from recent research in HF and their 

implications for heart failure research and treatment. 


12:30-1:30 PM 

How-to Sessions 

6. Using Apps for Self-Care 

Jill Howie Esquivel, San Francisco, CA 

Lorraine S. Evangelista, Los Angeles, CA 

Learning Objective: Describe the role of electronic applications in patient selfmanagement 

of heart failure. 

7. Cardiotoxicity of Chemotherapy: Evaluation and Therapy 

Jean-Bernard Durand, Houston, TX 

Anju Nohria, Boston, MA 

Learning Objective: Evaluate heart failure patients undergoing or recovering 

from chemotherapy and manage their disease. 

8. How to Read and Interpret the Results of Genetic Testing 

Neal Lakdawala, Boston, MA 

Anjali Tiku Owens, Philadelphia, PA 

Learning Objective: Identify the components of genetic testing results, their 

meaning, and their implications for patient care. 

9. How to Identify and Use Simple Tools for Assessment of Health Literacy 

Pamela N. Peterson, Denver, CO 

Ann S. Laramee, South Burhington, VT 

Learning Objective: Identify and use tools to assess health literacy and improve 

care in patients with heart failure. 

10. Heart Failure Physicians Learn to Read the ICD/CR Device Reports 

Bruce L. Wilkoff, Cleveland, OH 

TBN 

Learning Objective: To identify the components in the device reports most 

important for managing heart failure. 


2:00-3:30 PM 

Hyde Park Session 

Moderators: John G.F. Cleland, Kingston-Upon-Hull, UK 

Douglas D. Schocken, Durham, NC 

TBD 


Learning Objective: Discuss new insights and perspectives on heart failure research, 

education, and clinical practice. 


2:00-3:30 PM 

Back in the Hospital 

Moderators: Anita Deswal, Houston, TX 

Debra K. Moser, Lexington, KY 

2:00 Leading Up to Admission (ADHERE) 


2:15 Why is the Patient Back? 

Jason W. Ryan, Farmington, CT 

2:25 How is Comorbidity Associated with Readmission? 

Jill Howie Esquivel, San Francisco, CA 

2:35 What Else Can DOSE and ASCEND Teach Us? 

G. Michael Felker, Durham, NC 

2:45 ED Decision: Admit or Discharge to Early Follow-Up? 

Peter S. Pang, Chicago, IL 

3:00 How Much Patient Education and When? 

Lorraine S. Evangelista, Los Angeles, CA 


Learning Objective: Describe factors affecting readmission of patients with heart 

failure and implement strategies to improve readmission rates. 

21

22 


2:00-3:30 PM 

Therapies in Development 

Moderators: Steven Goldman, Tucson, AZ 

Michael J. Sole, Toronto, ON, Canada 

2:00* Where is there a Clinical Need? 

Arthur M. Feldman, Philadelphia, PA 

2:18* PKC Inhibitors are Ready for Heart Failure Trials! 

Jeffrey D. Molkentin, Cincinnati, OH 

2:36* Enough with the Kinases; Phosphatase Inhibitors for Heart 

Failure Therapy 

Yibin Wang, Los Angeles, CA 

2:54* Cell-Free Regenerative Therapies 

Annarosa Leri, Boston, MA 

3:12* Angiogenesis for Ischemic Heart Disease 

Douglas W. Losordo, Chicago, IL 


Learning Objective: Describe emerging therapies for heart failure and how they 

might be used to improve patient care. 


2:00-3:30 PM 

From Left to Right 

Moderators: Paul R. Forfia, Philadelphia, PA 

Robert P. Frantz, Rochester, MN 

2:00* Pulmonary Hypertension From HFpEF 

Margaret M. Redfield, Rochester, MN 

2:15* Primary, Reactive or Passive Pulmonary Hypertension 

TBN 

2:30* Lessons from Experimental Pulmonary Hypertension 

Jane A. Leopold, Boston, MA 

2:45* What Does the Right Ventricle Look Like? 

TBN 

3:00* Animal Models of Right Ventricle Overload 

Emily J. Tsai, Philadelphia, PA 

3:15* Right Ventricular Recovery 

Mandeep R. Mehra, Boston, MA 


Learning Objective: Describe pulmonary hypertension and right ventricular failure 

and identify appropriate management options. 


4:00-5:30 PM 

Debate Session 


Moderators: Marvin A. Konstam, Boston, MA 

Lynne Warner Stevenson, Boston, MA 

DEBATE: Oral Inotropic Agents Should be Available for Palliative Care 

4:00 Pro: Milton Packer, Dallas, TX 

4:15 Con: Milton Packer, Dallas, TX 

4:30 Questions from Moderators 

DEBATE: Clinical Care 

4:45 Clinical Care Should Focus More on Risk Stratification Tools* 

Wayne C. Levy, Seattle, WA 

5:00 Clinical Care Should Focus on More on Tools For Assessing 

Quality of Life* 

John A. Spertus, Kansas City, MO 

*Equal time should be given to all recognized tools. 

5:15 Questions from Moderators 

Learning Objective: Outline considerations influencing the use of inotropic agents in 

palliative care and tools for assessing risk and quality of life in patients with 

heart failure. 


4:00-5:30 PM 

Revised AHA/ACC Performance Measures and Evidence 

That Supports Changes 

Moderators: Nancy M. Albert, Cleveland, OH 

Mariell L. Jessup, Philadelphia, PA 

4:00 Impact of Performance Measures on Outcomes 

Christopher M. O’Connor, Durham, NC 

4:10 Heterogeneity of Performance 


4:20 Can We Adjust Populations to Measure Effectiveness? 

Soko Setoguchi-Iwata, Durham, NC 

4:30 When Guidelines Can Be Performance Measures 

Frederick A. Masoudi, Aurora, CO 

4:40 What the Community Physician Needs to Know 

Donald E. Casey, Jr., Morristown, NJ 

5:00 Strategy for Implementation of Outpatient Measures 

Clyde W. Yancy, Chicago, IL 


Faculty 

Learning Objective: Identify and assess current performance measures in heart 

failure and implement strategies for adherence.



4:00-5:30 PM 

Remodeling in Reverse 

Moderators: Michael R. Bristow, Denver, CO 


4:00 Changing Gene Expression with Medications 

Peter Buttrick, Denver, CO 

4:15 Changing Gene Expression with LVAD Support 

Kenneth B. Margulies, Philadelphia, PA 


4:35 The Dynamic Right Ventricle 

Michael R. Bristow, Denver, CO 


4:55 What Happens to Ventricular Function with Heart Failure 

Self Care 

Christopher S. Lee, Portland, OR 

5:10 Hemodynamic Remodeling During Home Monitoring 

William T. Abraham, Columbus, OH 


Learning Objective: Describe ways in which therapy can influence the genetic and 

physiological basis of heart failure and improve patient care. 


4:00-5:30 PM 

Drugs Don’t Work in Patients Who Don’t Take Them: 

Why Aren’t Patients Adherent? 


Robert Lee Page, II, Aurora, CO 

4:00 How Can Medication Adherence be Measured? 

Patricia A. Uber, Baltimore, MD 

4:18 Dosing Regimens 

Michael D. Murray, Indianapolis, IN 

4:36 Predicting Nonadherence 


4:54 Consequences of Poor Adherence 

Paul J. Hauptman, St. Louis, MO 

5:12 What Can We Do to Improve Adherence? 

Debra K. Moser, Lexington, KY 

Learning Objective: Measure patient adherence, identify variables contributing to 

non-adherence, and implement measures to improve adherence. 

WEDNESDAY 

Wednesday, September 12 

7:00-8:30 AM 

Clinical Fundamentals: 

Options for Advanced Heart Failure and Clinical Pearls 

Moderators: Tamara B. Horwich, Los Angeles, CA 

Josef Stehlik, Salt Lake City, UT 

7:00 When Is It Appropriate to Consider Referral for Advanced 

Heart Failure Therapies? 

Garrick C. Stewart, Boston, MA 

7:10 A Bridge to What? Choosing the Right Destination 

Jennifer Cowger, Ann Arbor, MI 

7:20 Mechanical Circulatory Support: Complications 

and Troubleshooting 


7:35 Cardiac Transplantation: Short- and Long-Term Outcomes 

and Implications for Patient Selection 

David DeNofrio, Boston, MA 

7:45 Cardiac Transplantation: Individualizing Immune Suppression 

Jon A. Kobashigawa, Los Angeles, CA 

8:00 Palliative Care and Shared Decision Making in Advanced 


Sarah J. Goodlin, Portland, OR 


Faculty 

8:15 Clinical Pearls 

Carl V. Leier, Columbus, OH 

Learning Objective: Evaluate heart failure patients for device implantation, manage 

implanted devices, and diagnose and treat pulmonary hypertension. 

23

24 


8:30-10:00 AM 

Cardiotoxicity 

Moderators: Anju Nohria, Boston, MA 

Paul Rosenberg, Durham, NC 

8:30* Why So Many Tyrosine Kinases? 

Thomas Force, Philadelphia, PA 

8:45* Cardiac Effects of Cytokines 


9:00* Cardiomyopathy of Substance Abuse 

George G. Philippides, Boston, MA 

9:15* Decreasing Toxicity of Anthracyclines 

Douglas B. Sawyer, Nashville, TN 

9:30* Toxicity of Nitric Oxide 

TBN 

9:45* Cardiac Risk of High Intensity Exercise 

Joseph R. Libonati, Philadelphia, PA 


Learning Objective: Evaluate heart failure patients for device implantation, manage 

implanted devices, and diagnose and treat pulmonary hypertension. 


8:30-10:00 AM 

Advances in Diagnosis and Targeted Management 

Strategies of Specific Cardiomyopathies 

Moderators: Edward M. Gilbert, Salt Lake City, UH 

Jacob Joseph, Boston, MA 

8:30 Current Management Strategies in Peripartum Cardiomopathy 

Uri Elkayam, Los Angeles, CA 

8:45 New Diagnostic and Management Strategies in Cardiac 

Amyloidosis: From Transthyretin Mutations to Bone Marrow 

or Liver Transplant 

TBN 

9:00 Treatment of Thalassemia and Iron Load Cardiomyopathies: 

What is New? 

JonDavid Menteer, Los Angeles, CA 

9:15 Prevention and Monitoring of Chemotherapy Induced 

Cardiomyopathies 

Jean-Bernard Durand, Houston, TX 

9:30 Rhythm Devices for Sarcoidosis 

William H. Sauer, Aurora, CO 

9:45 Panel Discussion: Role of Registries for Specific Conditions 

Learning Objective: Diagnose selected cardiomyopathies and evaluate available 

treatment strategies. 


8:30-10:00 AM 

Decreasing Readmission from Home 


Moderators: Peter E. Carson, Washington, DC 

Mariann R. Piano, Chicago, IL 

8:30* Facing the Front Line: Use of Community Health Workers 

Gia Mudd-Martin, Lexington, KY 

8:43* Integrating Care of Depression and Anxiety Into the Clinic 

Jared L. Skillings, Grand Rapids, MI 

8:56* Value Based Purchasing – Objects in Your Mirror Are Closer 

Than You Think! 

Mitchell T. Saltzberg, Newark, DE 


9:10 Old and New Biomarkers for Triage or Therapy? 

Alan S. Maisel, La Jolla, CA 

9:23 Update on Diuretic Infusions for Frequent Flyers 

Marie Galvao, Bronx, NY 

9:35 Non-Invasive Monitoring is Most Effective 

John G.F. Cleland, Kingston-Upon-Hull, UK 

9:45 Invasive Home Monitoring is Most Effective 

Robert C. Bourge, Birmingham, AL 


Learning Objective: Use home-based and community-based strategies to reduce 

readmission of the heart failure patient.



10:30 AM-12:15 PM 

Envisioning Therapy in Heart Failure 

Moderators: Eugene Braunwald, Boston, MA 

Gordon W. Moe, Toronto, ON, Canada 

10:30 Autonomic Modulation With Devices 

W.H. Wilson Tang, Cleveland, OH 

10:40 The Leadless Defibrillator 

Gust H. Bardy, Bellevue, WA 


10:55 Cardiology Patient Communities in Social Networks 

Leslie A. Saxon, Los Angeles, CA 

11:05 Monitoring Heart Failure Patient Symptoms and Signs 

through Smart Phones 

TBN 


11:20 Destination Therapy with Miniaturized Percutaneous VADs 

Daniel Burkhoff, New York, NY 


11:35 Bio-Nano-Chip Technology for Biomarker Assessment in 


John T. McDevitt, Houston, TX 

11:45 Implantable Monitoring Devices Close the Loop Directly 

With Patients 

William T. Abraham, Columbus, OH 


12:00 Comments: Vision for the Future: New and Renewed 

Eugene Braunwald, Boston, MA 

Learning Objective: Discuss emerging devices and networks and their potential 

impact on care of patients with heart failure. 


10:30 AM-12:00 PM 

Re-defining Success 

Moderators: Steven R. Goldsmith, Minneapolis, MN 

TBN 

10:30 Better Endpoints for New Therapies 

John R. Teerlink, San Francisco, CA 

10:40 Six Minute Walk for Pulmonary Hypertension, Why Not For 

Heart Failure? 

Mandeep R. Mehra, Boston, MA 


10:55 Evidence for Improved Quality of Care 

Nancy M. Albert, Cleveland, OH 


11:08 Prevalence and Prognosis of Heart Failure: Better EF 


11:18 Which Medications Can Be Stopped for Improvement and How? 

Mark A. Munger, Salt Lake City, UT 


11:35 Defining A Good Death 

Theo E. Meyer, Worcester, MA 

11:45 Evidence for Improving Survival in the Heart Failure Population 

Jonathan G. Howlett, Calgary, AB, Canada 


Learning Objective: Reassess common care endpoint in the treatment of heart failure 

and determine optimal approaches to care and management. 


10:30 AM-12:00 PM 

Common Sense and Personalized Medicine 

Moderators: Biykem Bozkurt, Houston, TX 


10:30 Do Survival Models Help in Decision Making? 

Larry A. Allen, Denver, CO 


10:43 Do Guidelines Distinguish Inpatients from Outpatients? 

Sharon A. Hunt, Stanford, CA 


10:56 When Do You Withhold a Recommended Therapy? 

Jalal K. Ghali, Detroit, MI 


11:25 When Does Quality of Life Conflict with Otherwise 

Optimal Therapy? 

Ronald M. Witteles, Stanford, CA 

11:40 Case Discussion 

Douglas D. Schocken, Durham, NC (Moderator) 

Eugene S. Chung, Cincinnati, OH 

John Chin, Sacramento, CA 

Learning Objective: Discuss optimal care of selected patients with heart failure 

based on evidence, guidelines, and reasonable outcomes. 

25

26 

phone: (651) 642-1633 

Fax: (651) 642-1502 

email info@hfsa.org 

Participant: please type or print clearly. aLL information requested is required. Incomplete forms will not be processed. payment in full must 

accompany registration. only one registrant per form. please make photocopies of this form for additional registrants. 

name (last, first, middle initial): degree: 

institution: 

address: 

city: state/province: zip/postal code: country: 

email address:* phone: fax: 

*Please enter email address carefully. It will be used for verification of attendance and access to credit certificates. 

Registration Fees: To take advantage of the membership rate for the 16th annual Scientific 

meeting individuals must have paid 2012 dues by June 15, 2012. See HFSa website (www.hfsa.org) 

for 2012 membership application. 

Members: advance after 7/30/12 code Amount 

md, do $595 $695 Fm $ 

phd $495 $595 Fp $ 

nurse/nurse practitioner $335 $435 Fn $ 

Health professional** $335 $435 FH $ 

pharmacist $335 $435 pH $ 

Fda/nIH $275 $375 Fg $ 

Trainee/resident* $165 $265 FT $ 

Nonmembers: advance after 7/30/12 code Amount 

md, do $850 $950 Fm $ 

phd $720 $820 Fp $ 

nurse/nurse practitioner $570 $670 Fn $ 

Health professional** $570 $670 FH $ 

pharmacist $570 $670 pH $ 

Fda/nIH $275 $375 Fg $ 

Trainee/resident* $275 $375 FT $ 

* student, fellow, post-doc (full-time status only, signed verification letter from program director required). Letter may 

be faxed to (651) 642-1502 or emailed to info@hfsa.org. Letters not received within 30 days of registering will result 

in cancellation of meeting registration. any penalties will apply. 

** dietitian, emS, nutritionist, oT, pa, pT, policy analyst, physiotherapist, technician/research technician, social worker 

Payment: 

meeTIng regISTraTIon Form 

16th annual Scientific meeting: September 9-12, 2012 

Washington State convention center, Seattle, Wa 

register online: www.hfsa.org (annual Scientific meeting) 

Registration Profile: 

registration form will not be accepted 

without this section completed. 

Check the category that best 

describes your profession: 

adult cardiologist 

pediatric cardiologist 

cv Surgeon 

ed physician 

Family/general practitioner 

Internist 

Hospitalist 

physician, other 

Scientist – phd 

Scientist (non-phd) 

pharmacist 

pharmacologist 

Technician/research Technician 

nurse/ nurse practitioner 

physician assistant 

non-medical 

other Health professional 

Work Environment: (Check One) 

academic Institution 

clinic 

government 

Hospital 

Industry 

private practice 

other Health care organization 

Credit card: If paying by credit card you must register online. registration may be paid by american express, visa or mastercard. 

Checks/Money Orders: complete the application and send with check or money order (in US dollars and from US banks only) payable to: 

Heart Failure Society of america (HFSa), court International, Suite 240 South, 2550 University avenue West, St.paul, mn 55114. 

Refunds: If notice of cancellation is received in writing prior to Friday, august 3, 2012, registration fee will be refunded less a $75 administrative 

charge. registration cannot be transferred. no refunds will be granted after august 3, 2012. 

updated 06/01/2012

2012 memberSHIp appLIcaTIon 

Note: To take advantage of the membership registration rate for the 

16th Annual Scientific Meeting (September 9-12, 2012, Seattle, WA) 

individuals must have paid 2012 dues by June 15, 2012. 

Applicant: please TYpe or prInT legibly and complete ALL information requested. 

name (last, first, middle initial): degree: 

mailing address: 

city: state/province: zip/postal code: country: 

phone: fax: email address: 

present hospital/university affiliation/firm/corporation: 

professional education and training 

(college, graduate or medical school, postgraduate training): dates attended degree 

present activity in the field of heart failure: 

list other society memberships: 

� check here if you do noT want your name, address or email to appear on mailing lists rented by 

vendors/third parties 

Membership: calendar year (Jan – dec). See website (www.hfsa.org) for membership benefits. 

� $300.00 Full members: mds, dos or equivalent who are in good standing in their respective communities, 

and are actively engaged in heart failure practice or research. 

� $200.00 Full members (other): all nonphysicians who are in good standing in their respective communities, 

and are actively engaged in heart failure practice or research. 

� $75.00 Trainees: open to individuals enrolled as "full-time" medical students, residents, fellows, undergraduate 

students, and pre- and post-doctoral trainees. a letter of verification, including the end of training date, from the 

training program direct is required with payment of dues for each year trainee membership is requested. 

Previous Member? � no � Yes 

Payment: dues may be paid with visa, mastercard, american express, check or money order (drawn 

on US banks only). checks or money orders are payable to: Heart Failure Society of america. 

� check � money order � american express � visa � mastercard 

account number: expiration date (mm/yy): 

name of cardholder: 

signature of cardholder: 

Court International, Suite 240 South Tel: (651) 642-1633 

2550 University Avenue West Fax: (651) 642-1502 

St. Paul, MN 55114 www.hfsa.org 

Check the category that best 

describes your profession: 

(check one) 

� adult cardiologist 

� pediatric cardiologist 

� cv Surgeon 

� ed physician 

� Family/general practitioner 

� Internist 

� Hospitalist 

� physician, other 

� Scientist – phd 

� Scientist (non-phd) 

� pharmacist 

� pharmacologist 

� Technician/research Technician 

� nurse/ nurse practitioner 

� physician assistant 

� non-medical 

� other Health professional 

Work Environment: (check one) 

� academic Institution 

� clinic 

� government 

� Hospital 

� Industry 

� private practice 

� other Health care organization 

none of the payment is deductible as a charitable contribution but may be deductible as an ordinary and necessary business expense. 

27

Heart Failure Society of America 

nonprofit 

US postage 

paid 

permit 100 

mpLS mn 

Court International, Suite 240 South 

2550 University Avenue West 

St. Paul, MN 55114 

16th Annual Scientific Meeting 

Advance Program & Registration Information 

September 9 – 12, 2012 

Washington State Convention Center 

Seattle, WA 

www.hfsa.org

Download - Heart Failure Society of America

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?